Moreover, BCA2 regulates the tumor suppressor IRF1 independently of its SUMO E3 ligase activity, causing IRF1 activation in ER-positive and IRF1 downregulation in ER-negative breast cancers, which may explain the contradictory observations reported in relation to the role of BCA2 in breast cancer [47]. Here, IRF1 is linked to breast carcinoma.